OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Oral Presentation Highlights the Results of a Phase II/III Trial of the Investigational Immunotherapy OBI-822/OBI-821 in Patients with Metastatic Breast Cancer TAIPEI, TAIWAN, May 19, 2016 – OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced that the company-sponsored abstract detailing the full results of its Phase II/III study of OBI-822/OBI-821 (formerly OPT-822/OPT-821) […]

This article is password protected.

To view the content, please enter your password in the field below